https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-900
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-08 / Cancer Immunol. Immunother. 2009 Jun;58(6):887-9002008-11-08 00:00:002021-11-15 17:03:25Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-05 / Int. J. Radiat. Oncol. Biol. Phys. 2009 Jan;73(1):242-502008-11-05 00:00:002019-02-15 08:35:19Radiotherapy and hyperthermia for treatment of primary locally advanced cervix cancer: results in 378 patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Zhong Nan Da Xue Xue Bao Yi Xue Ban 2008 Nov;33(11):1012-82008-11-01 00:00:002019-02-15 09:19:15[Activation of anti-tumor cytotoxic T lymphocytes by fusion of human dendritic cells and melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-11-01 / Urol. Oncol. 2008 Nov-Dec;26(6):576-802008-11-01 00:00:002019-02-15 09:23:59Dendritic cell vaccines for the treatment of prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-25 / Cancer Immunol. Immunother. 2009 Jun;58(6):901-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-25 / Cancer Immunol. Immunother. 2009 Jun;58(6):901-132008-10-25 00:00:002019-02-15 08:44:25Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-403
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-23 / Exp. Dermatol. 2009 Apr;18(4):396-4032008-10-23 00:00:002019-02-15 09:19:13The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-10
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-18 / Neurol. Res. 2009 Feb;31(1):3-102008-10-18 00:00:002019-02-15 09:00:15Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-08 / Clin. Immunol. 2008 Dec;129(3):482-912008-10-08 00:00:002019-02-15 09:19:18Dendritic cells pulsed with keyhole limpet hemocyanin and cryopreserved maintain anti-tumor activity in a murine melanoma model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-02 / Cell. Immunol. 2009;254(2):135-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-02 / Cell. Immunol. 2009;254(2):135-412008-10-02 00:00:002019-02-15 09:02:59The anti-tumor effect of human monocyte-derived dendritic cells loaded with HSV-TK/GCV induced dying cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-10-01 / J. Immunother. 2008 Oct;31(8):771-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-10-01 / J. Immunother. 2008 Oct;31(8):771-802008-10-01 00:00:002019-02-15 09:16:52Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial
